Abstract
Intarest for L(-)-β(3,4-dihydroxypherl)aianine (L(-)-DOPA)as a therapautic in the treatment of parkinson's disease has resulted in a large number of papers, speically in the partent litsrature, concerning of ± -DOPA or of raomic derivatines 1–11.